LETTER TO THE EDITOR

DOI: 10.4274/tjh.galenos.2025.2025.0318

A Rare Autoimmune Quartet: Immune Thrombocytopenia in a Patient with Autoimmune Polyglandular Syndrome Type 3

Ünal Ataş¹, Hakan Doğruel²

¹Akdeniz University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya, Türkiye

²Antalya City Hospital, Clinic of Internal Medicine, Division of Endocrinology and Metabolism, Antalya, Türkiye

Ünal Ataş, M.D., Akdeniz University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya, Türkiye vrlunalatas@gmail.com 0000-0001-5897-6514

July 27, 2025 September 24, 2025

Letter to editor,

Autoimmune polyglandular syndromes (APS) comprise a group of disorders characterized by the autoimmune-mediated dysfunction of multiple endocrine glands. Key endocrine pathologies include hypoparathyroidism, adrenal insufficiency, type-1 diabetes mellitus (DM), and hypothyroidism. Non-endocrine manifestations, such as mucocutaneous candidiasis, alopecia, vitiligo, celiac disease, and autoimmune gastritis (pernicious anemia), are also observed.^{1,2} However, the coexistence of hematologic autoimmune conditions, such as immune thrombocytopenia or autoimmune hemolytic anemia, is exceedingly rare within the APS spectrum.³ APS is currently categorized into four main types (Table 1).^{1,2} APS type 3 is defined by the presence of autoimmune thyroid disease in association with another organ-specific autoimmune condition, excluding adrenal insufficiency and hypoparathyroidism. We report a unique case of APS type 3 in a young woman with a history of immune thrombocytopenia, type-1 DM, Hashimoto's thyroiditis, and myasthenia gravis (MG). In addition to the endocrine-based classification, this constellation is also consistent with multiple autoimmune syndrome (MAS) type 3, a category that elosely parallels APS type 3 in the literature.⁴

A 25-year-old woman presented for routine follow-up of immune thrombocytopenia. She had been diagnosed two years earlier and initially treated with corticosteroids. One year ago, during the first month postpartum, she experienced a relapse and received intravenous immunoglobulin (IVIG) along with steroids. Three months after discontinuing steroids, the patient experienced a relapse requiring retreatment. After breastfeeding cessation, a subsequent relapse necessitated four doses of rituximab (375 mg/m²/week). Further review of her medical history revealed that she had been diagnosed with type-1 DM and Hashimoto's thyroiditis at the age of 18. Additionally, the diagnosis of MG was established three years ago based on typical clinical findings and compatible electromyographic results, and she was subsequently treated with steroids and IVIG. She remained asymptomatic for MG during rituximab therapy, achieved a complete response for immune thrombocytopenia (platelet count >100×10°/L at last follow-up), and continued her maintenance therapy for MG thereafter. Her current medications include insulin, levothyroxine, and pyridostigmine. Physical examination was unremarkable, and laboratory findings showed no signs of thrombocytopenia or anemia. The combination of autoimmune thyroiditis, type-1 DM (type 3a), and MG (type 3c) satisfies the diagnostic criteria for APS type 3. Taken together, these findings also place the patient within the expanded framework of MAS type 3. Although rare, her concurrent diagnosis of immune thrombocytopenia requiring second-line therapy further highlights the complexity of her autoimmune profile.

Immune thrombocytopenia, usually considered a primary hematologic disorder, can also develop due to identifiable secondary causes such as infections, medications, or systemic disorders, including autoimmune diseases.⁵ In this context, the coexistence of immune thrombocytopenia with APS, though rare, is a relevant consideration, especially in young patients with multiple autoimmune features. Immune thrombocytopenia accompanying Graves' disease, which does not meet the definition of APS, has been reported rarely.^{6,7} A previously reported case fulfilling the definition of APS included autoimmune hyperthyroidism and type-1 DM,

along with both immune thrombocytopenia and heparin-induced thrombocytopenia.³ However, our literature search did not identify any previous reports describing the specific combination of type-1 DM, MG, Hashimoto's thyroiditis, and immune thrombocytopenia.

Interestingly, our patient, who had type-1 DM (type 3a component), MG (type 3c component without vitiligo), and autoimmune thyroiditis in the absence of adrenal insufficiency, also had a history of immune thrombocytopenia that required second-line treatment. APS-3 and MAS-3 share considerable overlap, although MAS generally encompasses a wider range of non-endocrine autoimmune conditions.⁴ This constellation fulfills the diagnostic criteria for APS type 3 (3a+3c) and, given the coexistence of additional autoimmune disorders such as immune thrombocytopenia, can also be classified within the spectrum of MAS type 3. Despite its rarity, clinicians should maintain a high index of suspicion for underlying endocrinopathies in patients with immune thrombocytopenia, as it may represent a component of APS or MAS.

Keywords: Autoimmune polyglandular syndromes, Immune thrombocytopenia, Hashimoto's thyroiditis, Type-I diabetes mellitus, Myasthenia gravis

Conflict of Interest: The authors declare no conflicts of interest.

Funding Sources: There was no funding in conjunction with the preparation of this manuscript.

References

- 1. Sperling MA, Angelousi A, Yau M. Autoimmune Polyglandular Syndromes. 2024 Jul 21. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000—.
- 2. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002 Jun;23(3):327-64.
- 3. Kinoshita T, Kamei S, Nakamura Y, et al. Onset of type 1 diabetes mellitus and heparin-induced thrombocytopenia in a patient with Basedow's disease and idiopathic thrombocytopenic purpura: Novel combination as autoimmune polyglandular syndrome. J Diabetes Investig. 2018 Nov;9(6):1381-1382.
- 4. Betterle C, Furmaniak J, Sabbadin C, Scaroni C, Presotto F. Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding galaxy. J Endocrinol Invest. 2023 Apr;46(4):643-665. doi: 10.1007/s40618-022-01994-1.
- 5. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, Kühne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 Dec 10;3(23):3829-3866.
- 6. Marta GN, de Campos FP. Immune thrombocytopenia and autoimmune thyroid disease: a controversial overlap. Autops Case Rep. 2015 Jun 30;5(2):45-8.
- 7. Agyapong KO, Folson AA, Fiador K, Kootin-Sanwu C, Tufuor M, Bampoh SA, Fiscian H, Wonkyi R. Graves' disease-induced immune thrombocytopenic purpura in an African female: a case report. J Med Case Rep. 2023 Apr 5;17(1):122.

Table 1. Classification of autoimmune polyglandular syndrome (APS)^{1,2}

Table 1. Classification of autominiane polygiandalar syndrome (1115)	
APS Type 1 (APECED) *	Chronic mucocutaneous candidiasis, hypoparathyroidism,
	autoimmune adrenal insufficiency
APS Type 2 (Schmidt syndrome) **	Autoimmune adrenal insufficiency, autoimmune thyroid disease,
	type-1 diabetes mellitus
APS Type 3***	Autoimmune thyroid disease, other autoimmune diseases
	(excluding autoimmune adrenal disease, hypoparathyroidism)
APS Type 4****	≥2 organ specific autoimmune disease (which not meeting type 1,
	type 2 and type 3 criteria)

APECED: autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;

- * Diagnosis requires two components. Type-1A diabetes, primary hypogonadism, pernicious anemia, autoimmune hepatitis, ovarian failure, pure red cell aplasia, alopecia, and vitiligo, may also be present.
- ** Diagnosis requires autoimmune thyroid diseases and/or type-1 diabetes mellitus in addition to the presence of autoimmune adrenal insufficiency. Primary hypogonadism, myasthenia gravis, and celiac disease also are commonly observed.
- *** APS type 3 was defined as the association between one of the clinical entities of the autoimmune thyroid diseases (Hashimoto's thyroiditis, idiopathic myxedema, symptomless autoimmune thyroiditis, Graves' disease, endocrine ophthalmopathy) and one or more of other autoimmune diseases [type 1 diabetes mellitus (type 3a); atrophic gastritis, pernicious anemia (type 3b); vitiligo, alopecia, myasthenia gravis (type 3c); systemic autoimmune connective tissue diseases (systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, systemic sclerosis, antiphospholipid syndrome, vasculitis...) (type 3d)].

 *****Combination of autoimmune diseases which do not fall into type 1, type 2 and type 3.